Anti uchl5

bAP15 (11324) was purchased from Cayman Chemical (Ann Arbor, MI). The USP14 inhibitor IU1 (662210) was obtained from EMD Millipore Corporation (Billerica, MA). UCHL5 shRNA plasmid (h) (sc-76797-SH) was purchased from Santa Cruz Biotechnology (Dallas, TX). HA-ubiquitin (Plasmid 18712) was purchased from Addgene (Cambridge, MA).
Antibodies were obtained as follows; anti-β-actin (sc-47778), anti-UCHL5 (sc-271002), anti-USP14 (sc-100630), anti-β-catenin (sc-7963), anti-Vimentin (sc-6260), anti-Ub (sc-166553), and anti-HA-probe (F-7) (sc-7392) (Santa Cruz Biotechnology), anti-E-cadherin (610181), anti-N-cadherin (610920)(BD Bioscience, San Jose, CA), anti-Smad2 (5339), anti-Phospho-Smad2 (3108), anti-Phospho-Smad2 (18338), anti-Smad3 (9523), anti-Phospho-Smad3 (9520), and anti-Smad4 (38454) (Cell Signaling Technology, Danvers, MA).

TGF-β1 (209-16554) was purchased from Fujifilm Wako Pure Chemical Industries (Osaka, Japan), and bAP15 (11324) was purchased from Cayman Chemical (Ann Arbor, MI, USA). The following antibodies were used: anti-β-actin (sc-47778), anti-UCHL5 (sc-271002), anti-Vimentin (sc-6260; Santa Cruz Biotechnology, Dallas, TX, USA), anti-E-cadherin (610181; BD Bioscience, San Jose, CA, USA), anti-smad1 (6944), anti-Phospho-Smad1 (5753), anti-Smad2 (5339), anti-Phospho-Smad2 (3108), anti-Phospho-Smad2 (18338), anti-Smad3 (9523), anti-Phospho-Smad3 (9520), anti-Smad4 (38454), anti-smad5 (12534), anti-Phospho-smad1/5 (9516), anti-Phospho-smad1/5/9 (13820), anti-ERK (9102), anti-Phospho-ERK (9101), anti-AKT (4691), anti-Phospho-AKT (4060; Cell Signaling Technology, Danvers, MA, USA), and anti-smad7 (216428; Abcam Inc., Toronto, ON, Canada).